Eiger Non Currrent Assets Other from 2010 to 2024
Eiger Biopharmaceutica Non Currrent Assets Other yearly trend continues to be relatively stable with very little volatility. Non Currrent Assets Other are likely to drop to about 342 K. Non Currrent Assets Other is assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents. View All Fundamentals
This module can also supplement Eiger Biopharmaceutica's financial leverage analysis and stock options assessment as well as various Eiger Biopharmaceutica Technical models . Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
Non Currrent Assets Other | First Reported 2012-12-31 | Previous Quarter 144 K | Current Value 360 K | Quarterly Volatility 1.7 M |
Check Eiger Biopharmaceutica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eiger main balance sheet or income statement drivers, such as Depreciation And Amortization of 712.5 K, Interest Expense of 5.7 M or Selling General Administrative of 15.7 M, as well as many exotic indicators such as Price To Sales Ratio of 0.6, Dividend Yield of 0.0 or Days Sales Outstanding of 60.03. Eiger financial statements analysis is a perfect complement when working with Eiger Biopharmaceutica Valuation or Volatility modules.
Eiger | Non Currrent Assets Other |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eiger Biopharmaceutica in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eiger Biopharmaceutica's short interest history, or implied volatility extrapolated from Eiger Biopharmaceutica options trading.
Pair Trading with Eiger Biopharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eiger Biopharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eiger Biopharmaceutica will appreciate offsetting losses from the drop in the long position's value.Moving together with Eiger Stock
| 0.71 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.77 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Eiger Stock
| 0.66 | ACB | Aurora Cannabis Downward Rally | PairCorr |
| 0.55 | HCM | HUTCHMED DRC | PairCorr |
| 0.5 | CGC | Canopy Growth Corp Downward Rally | PairCorr |
The ability to find closely correlated positions to Eiger Biopharmaceutica could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eiger Biopharmaceutica when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eiger Biopharmaceutica - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eiger Biopharmaceuticals to buy it.
The correlation of Eiger Biopharmaceutica is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eiger Biopharmaceutica moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eiger Biopharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eiger Biopharmaceutica can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Eiger Biopharmaceuticals information on this page should be used as a complementary analysis to other Eiger Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Eiger Stock analysis
When running Eiger Biopharmaceutica's price analysis, check to measure Eiger Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eiger Biopharmaceutica is operating at the current time. Most of Eiger Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Eiger Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eiger Biopharmaceutica's price. Additionally, you may evaluate how the addition of Eiger Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Eiger Biopharmaceutica's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eiger Biopharmaceutica. If investors know Eiger will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eiger Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (58.50) | Revenue Per Share 9.951 | Quarterly Revenue Growth (0.20) | Return On Assets (0.52) | Return On Equity (2.26) |
The market value of Eiger Biopharmaceuticals is measured differently than its book value, which is the value of Eiger that is recorded on the company's balance sheet. Investors also form their own opinion of Eiger Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Eiger Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eiger Biopharmaceutica's market value can be influenced by many factors that don't directly affect Eiger Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eiger Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eiger Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eiger Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.